4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nanobiotix S.A. (NANO) operates in the Biotechnology industry and is headquartered in Paris, France with about 100 employees. Its market capitalization is roughly €2 billion. In the fiscal year ended 2025-12-31, NANO reported €30M in revenue and (€24M) in net income.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €30M | (€12M) | €30M | €0M | — |
| Operating Income (EBIT) | (€11M) | (€68M) | (€27M) | (€47M) | — |
| Net Income | (€24M) | (€68M) | (€40M) | (€57M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | €0M | €0M | €0M | €0M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €68M | €67M | €94M | €60M | — |
| Total Liabilities | €152M | €133M | €96M | €87M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NANO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms